Prostate Cancer Coverage from Every Angle

Rebiopsy for Prostate Cancer: Can Some Men With Negative MRI Avoid It?

By: Susan Reckling
Posted: Monday, October 8, 2018

Andre Luis de Castro Abreu, MD, of the USC Institute of Urology, Keck School of Medicine, University of Southern California, Los Angeles, and colleagues suggest that a subset of men with negative magnetic resonance imaging (MRI) may be able to safely avoid rebiopsy. These men, who have a favorable prostate-specific antigen (PSA) density and prior negative biopsy, may be able to avoid biopsy-related morbidity and overdiagnosis of prostate cancer, the investigators indicated. These prospective cohort findings were published in The Journal of Urology.

“Conversely, prostate biopsy should be considered in biopsy-naïve men, regardless of negative [multiparametric] MRI, particularly those with a PSA density of greater than 0.15 ng/mL/cc,” the investigators noted.

A total of 1,149 consecutive men undergoing prostate biopsy (from October 2011 to March 2017) were the focus of this single-institution study, with 135 having a prebiopsy negative multiparametric MRI. The investigators used PSA density and prior biopsy history to evaluate the detection of clinically significant prostate cancer.

Among all the men with negative MRI, 18% were found to have clinically significant prostate cancer. When combined with a PSA density of less than 0.15 ng/mL/cc and a history of prior negative prostate biopsy, the negative predictive value for a negative MRI was 100%. Independent predictors of the absence of clinically significant prostate cancer included smaller prostates, higher PSA density, and no history of prior negative biopsy.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.